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INTRODUCTION
Pleomorphic carcinoma (PC) is a rare tumor of the lung. It accounts for 0.1-1 % of all pulmonary malignant tumors (1, 2) . According to the 2004 World Health Organization classification of lung tumors, pleomorphic carcinoma is one of five subgroups of pulmonary sarcomatoid carcinoma (3) . An accurate preoperative diagnosis of this tumor by bronchoscopic or transthoracic needle biopsy is difficult due to the heterogeneity of the tumor (4) . Many case reports but very few studies have been published in the literature regarding clinical and pathological characteristics of pulmonary pleomorphic carcinoma. As a result its clinical and pathological characteristics are not well known (2, 5) . The purpose of the present study was to evaluate clinicopathological characteristics and treatment outcomes of patients with pleomorphic pulmonary carcinoma.
METHODS

This retrospective study was conducted at Süreyyapaşa Chest Diseases and Thoracic Surgery
Training and Research Hospital, Istanbul, Turkey. The study was approved by the local scientific committee of institute. The records of pathology department from January 2005 to December 2013 were reviewed. Twenty-one cases of pleomorphic pulmonary carcinoma were identified during this period. All the pathological material was reexamined by an expertise pathologist. Hematoxylin and eosin stained slides were present in all cases.
Immunohistochemical staining was performed in 18 cases. The diagnosis of pulmonary pleomorphic carcinoma was based on the criteria set by World Health Organization (3). One patient was excluded from this study because the tumor didn't meet the criteria set by World Health Organization. Thus, the present study included 20 cases of pleomorphic carcinoma.
The patients' clinical files were evaluated for the following: age, gender, history of smoking, symptoms, radiological features, diagnostic investigations, pathological findings, stage of the tumor, treatment, and outcomes.
All patients underwent routine laboratory studies, electrocardiography, chest-x ray, computed tomography (CT) of the thorax, and fiberoptic bronchoscopy. CT-guided transthoracic fine needle aspiration (TFNA) was performed in nine patients. Pulmonary function tests were performed in patients who underwent a surgical procedure. Statistical analysis: The overall survival rate was calculated by using the Kaplan-Meier method.
RESULTS
There were 18 (90 %) male and 2 (10 %) female patients (male to female ratio, 9 to1). The mean age was 63.4 years (range 38-81 years). Eighteen (90 %) patients had smoking history.
All patients were symptomatic. The most common symptom was chest pain, followed by dyspnea. The clinical data was given in table 1. Nearly 1100 cases with primary pulmonary malignancy have been diagnosed annually in our center. According to these results, its incidence is 0.2 % in our center.
Pleomorphic carcinoma predominantly occurs in elderly men who smoke heavy, as similar as our findings (7-9). The male:female ratio ranges from 2.3:1 to 10.3:1 (5,7). The mean age at diagnosis is 57-66 years (9, 10) . There is strong association of this tumor with cigarette smoking. The rate of the smoker patients is between 80 %-95 % (4, 5) . Most patients present with nonspecific pulmonary symptoms including chest pain, cough, hemoptysis, and dyspnea, whereas they can be asymptomatic for a long time (4-6, 11, 12). Chang et al (13) reported that all patients presented with one or more symptoms. Two previous reports noted that symptoms were seen in 72.7 % and 90 % of the patients (5, 6). In our series, all patients were symptomatic. Symptoms are associated with the location and size of the tumor.
Pulmonary pleomorphic carcinomas are classified either as central endobronchial type or peripheral parenchymal type on the basis of the location of the tumor. Central type produces several symptoms as a result of bronchial irritation, obstruction or obstructive pneumonia.
Peripheral type produces symptoms due to the early pleural and chest wall invasion (7, 11, 13) . Pleomorphic carcinomas tend to be large peripheral tumors, as in our series. They are often found as a large mass, more than 4-5 cm in diameter. Large tumors are usually symptomatic (6, 11) . We conclude that pulmonary symptoms may associated with smoking in many smoker patients.
The radiological findings of pulmonary pleomorphic carcinoma are nonspecific and similar to those of other primary lung cancers. Most patients present with a solitary pulmonary mass or nodule on radiographs and CT. The images frequently demonstrate intratumoral cavities (6, 10, 13) . While the lesions are generally unilateral and solitary, bilateral or multiple lesions can be identified on radiographic images (11) . There is a predilection for peripheral location and upper lobes (7, 10) . Those findings are consistent with those in our series.
The preoperative diagnosis of pleomorphic carcinoma is very difficult because the diagnostic value of preoperative diagnostic methods including bronchoscopy and transthoracic needle aspiration is limited (4) (5) (6) (7) 14) . Yamamato et al (4) reported that none of the patients had a preoperative diagnosis of pleomorphic carcinoma. Ito et al (6) noted that transbronchial biopsy was diagnostic in three of 22 cases and there were no cases diagnosed with cytological examination. This is due to the heterogeneity and rare incidence of this tumor (7, 14) . Bronchoscopy and transthoracic fine needle aspiration can yield small amount of tissue for pathological examination. Also, they often demonstrate only one component of the tumor. As a result, a definitive diagnosis is established based on examination of surgical specimens in the majority of the cases (5, 7) . In our series, only two patients had preoperative diagnosis of pleomorphic carcinoma. The definitive diagnosis was established with examination of surgical specimens in remaining 18 patients.
Pleomorphic carcinoma presents an aggressive behavior. At the time of presentation, local invasion of adjacent structures, metastasis to hilar and mediastinal lymph nodes, and distant metastases are frequent (5-7, 13). Chang et al (13) reported that among seven of the patients who underwent surgical resection, four of them had mediastinum, pleura and chest wall invasions and three of them had regional lymph node metastases. Mochizuki et al (9) noted that vascular invasion and lymph node metastases were observed in 86 % and 41 % of the patients, respectively. They reported that 7 % of the patients had the pathological stage IV.
According to Fishback's report (11), 12 % of the patients had stage IV lesions at the time of diagnosis. In our series, four patients had chest wall invasion. There were N1 lymph node metastases in two patients and N2 lymph node metastases in two patients. Four patients had distant metastases at the time of presentation. Pleural effusion was diagnosed in one patient with distant metastases.
Complete surgical resection of the tumor with clear tumor margins is the treatment of choice in especially early stage patients with pulmonary pleomorphic carcinoma (4-7, 9, 11, 13). Raveglia et al (5) suggested that surgery for preoperatively proven pulmonary pleomorphic carcinoma should be restricted to N0 patients. Adjuvant and neoadjuvant chemotherapy and radiotherapy are controversial and they can be considered in selected cases (4) (5) (6) (7) 13) . The rate of local recurrence and distant metastases after surgery are high (6, 7, 9, 15) . Mochizuki et al (9) reported that twenty-four patients had died as a result of distant metastases or recurrence 27 days to 36 months after surgery. Raveglia et al (5) noted that sixteen of 20 patients died from early distant metastases after surgery. Pleomorphic carcinoma have a worse prognosis than the other non-small cell carcinoma cases (7, 9) . The overall 5-year survival rate, median survival time, disease-free survival rate, and median disease-free survival time were 36.7 %, 22.8 months, 40.8 %, and 14.7 months, respectively (9) . Five-year overall survival was found as 39.2 % in other study (7) . Prognosis can be associated with several factors. These factors include location, size, and stage of the tumor, the presence of distant metastases and lymph node metastases (5, 9, 11, 13) . The central type have better prognosis than peripheral type because of their limited extension to the surrounding parenchyma and there are early symptoms. Early dissemination is more frequent in the peripheral type (13) . The size of tumor greater than 5 cm, stage greater than 1 at presentation, the presence of any lymph node metastases and distant metastases indicate a poor prognosis for survival (5, 11) . In our series, most patients had one or more of poor prognostic factors.
The median survival time was 6 months. Survival time for 11 patients was six months or shorter than six months.
In conclusion, pleomorphic carcinoma is a rare tumor of the lung. Pathologic diagnosis of this tumor is usually established by surgical biopsy. The prognosis of patients with pleomorphic pulmonary carcinoma is poor despite complete surgical resection. Figure: The cumulative survival graph.
